Barclays Maintains an 'Overweight' on CVS Caremark (CVS); Positive on Shares After Mee ing

May 25, 2012 2:01 PM EDT
Get Alerts CVS Hot Sheet
Price: $83.54 -0.45%

Rating Summary:
    21 Buy, 8 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade CVS Now!
Join SI Premium – FREE
Barclays maintains an 'Overweight' on CVS Caremark (NYSE: CVS) price target of $50.00.

Analyst, Meredith Adler, said, "Earlier this week we hosted CVS' CFO, Dave Denton and its SVP of Investor Relations, Nancy Christal, in meetings with European investors. Management re-iterated previous guidance that the dispute between Walgreen and Express Scripts would benefit 2Q results by $0.03-$0.04 but that 2H12 guidance includes no benefit, even though they seemed confident that much of the new business would be retained even if the dispute was resolved."

Alder sees CVS making progress on several fronts, and believes in the company's manangement, but she feels the current share price isn't reflecting the positive outlook.

For an analyst ratings summary and ratings history on CVS Caremark click here. For more ratings news on CVS Caremark click here.

Shares of CVS Caremark closed at $45.17 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Mergers and Acquisitions

Related Entities


Add Your Comment